M&A / Deals

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

BioPharma Dive

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the next wave of care for immunological conditions.

Immunology & Inflammation

Read full story

pharminent May 4, 2026 (Last updated: May 4, 2026)

BioPharma Dive

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the next wave of care for immunological conditions.

Immunology & Inflammation

Read full story

Related Stories

Eli Lilly to Acquire Kelonia Therapeutics

LEO Pharma to acquire gene therapy company Replay

Two biotechs raise a combined $556M in latest spurt of IPOs

You May Have Missed

Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq

223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease

Eli Lilly to Acquire Kelonia Therapeutics

Gene therapy’s evidence problem–lessons from recent FDA decisions